A/Prof. Cornelia Landersdorfer (Australia)
A/Prof. Cornelia Landersdorfer, PhD, is an Associate Professor at the Monash Institute of Pharmaceutical Sciences, Monash University. She leads a research group that integrates dynamic in vitro infection experiments with molecular studies and mechanism-based mathematical modelling to optimise dosing of antibiotics against critical Gram-negative pathogens. Her group also designs and analyses population pharmacokinetic/pharmacodynamic studies for antibiotics and other drugs. Her research has generated new knowledge on the pharmacokinetics of polymyxins in different patient groups, as well as their pharmacokinetics/pharmacodynamics in in vitro and in vivo studies. She has >140 peer-reviewed publications, and was awarded the Georgina Sweet Award for Women in Quantitative Biomedical Sciences in 2018. A/Prof Landersdorfer is Academic Deputy Director of the Monash-Moderna Quantitative Pharmacology Accelerator. Her research is supported by NHMRC, ARC, NIH and pharmaceutical industry, and has informed dosing guidelines and patient therapy internationally.
A/Prof. Cornelia Landersdorfer, PhD, is an Associate Professor at the Monash Institute of Pharmaceutical Sciences, Monash University. She leads a research group that integrates dynamic in vitro infection experiments with molecular studies and mechanism-based mathematical modelling to optimise dosing of antibiotics against critical Gram-negative pathogens. Her group also designs and analyses population pharmacokinetic/pharmacodynamic studies for antibiotics and other drugs. Her research has generated new knowledge on the pharmacokinetics of polymyxins in different patient groups, as well as their pharmacokinetics/pharmacodynamics in in vitro and in vivo studies. She has >140 peer-reviewed publications, and was awarded the Georgina Sweet Award for Women in Quantitative Biomedical Sciences in 2018. A/Prof Landersdorfer is Academic Deputy Director of the Monash-Moderna Quantitative Pharmacology Accelerator. Her research is supported by NHMRC, ARC, NIH and pharmaceutical industry, and has informed dosing guidelines and patient therapy internationally.